TriangleNCT00465985 · OUTCOME
Pharmacodynamics Measured by Interleukin-1β (IL-1β) Concentrations at End of Part II.
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- pg/mL
- Interval / dispersion
- Standard Deviation
- Time frame
- 32 weeks after study start
Analysis population: Intention to treat (ITT) population.
Groups in this outcome
ACZ885
ACZ885 150 mg subcutaneous injection or 2 mg/kg subcutaneous injection, depending on body weight, every 8 weeks.
Placebo
Placebo subcutaneous injection every 8 weeks.
| Group | Source count |
|---|---|
| ACZ885 | 15 |
| Placebo | 16 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| ACZ885 | 21.943 | 10.3698 | Not reported | Not reported | Not reported |
| Placebo | 0.596 | 0.7289 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 10.3698
- value
- 21.943
- group Id
- OG001
- spread
- 0.7289
- value
- 0.596
- denoms
- counts
- group Id
- OG000
- value
- 15
- group Id
- OG001
- value
- 16
- units
- Participants
- dispersion Type
- Standard Deviation
- groups
- description
- ACZ885 150 mg subcutaneous injection or 2 mg/kg subcutaneous injection, depending on body weight, every 8 weeks.
- id
- OG000
- title
- ACZ885
- description
- Placebo subcutaneous injection every 8 weeks.
- id
- OG001
- title
- Placebo
- param Type
- MEAN
- population Description
- Intention to treat (ITT) population.
- reporting Status
- POSTED
- time Frame
- 32 weeks after study start
- title
- Pharmacodynamics Measured by Interleukin-1β (IL-1β) Concentrations at End of Part II.
- type
- SECONDARY
- unit Of Measure
- pg/mL
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice